ReviewFrontiers in immunology2022
Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Global Research Trends and Insights on AI Usage in Tuberculosis: Bibliometric Analysis.JMIR medical informatics · 2026Article
- A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis.Annals of clinical microbiology and antimicrobials · 2026Article
- Accuracy of the Phenotypic 1G Test to Detect Mycobacterium tuberculosis and Drug Resistance From Sputa in the US-Mexico Border.The Journal of infectious diseases · 2026Article
- Optimizing drug-resistant tuberculosis diagnosis: cost-effectiveness of rapid molecular and phenotypic assays in South Africa.BMC medicine · 2026Article
- Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis.PloS one · 2026Article
- Whole-genome sequencing reveals lineage-associated drug resistance and enables machine learning-based prediction inFrontiers in microbiology · 2026Article
- Rapid Extensively Drug-Resistant (XDR) TB Diagnosis: An In-House DNA Biochip for Drug Resistance Detection and Mutation Profiling ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- From mutation detection to treatment decisions: CRISPR-enabled diagnostics for drug-resistant tuberculosis.Frontiers in bioengineering and biotechnology · 2026Review
- Whole genome sequencing-based detection of extensively drug-resistant tuberculosis from Ethiopia.Communications medicine · 2025Article
- Article
- Article
- Whole-genome sequencing for analyzing the transmission characteristics of drug-resistant Mycobacterium tuberculosis in Ganzhou, China.BMC infectious diseases · 2025Article
- Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB.Antibiotics (Basel, Switzerland) · 2025Article
- Genotyping and transmission analysis of Mycobacterium tuberculosis in a pediatric population in Czech Republic and Slovakia.BMC infectious diseases · 2025Article
- Rapid detection of rifampin resistance inMicrobiology spectrum · 2025Article
- Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours.Nature communications · 2025Article
- Rapid antimicrobial susceptibility testing using carbon screen printed electrodes in a microfluidic device.Scientific reports · 2025Article
- Diagnosis of nontuberculous mycobacterial infections using genomics and artificial intelligence-machine learning approaches: scope, progress and challenges.Frontiers in microbiology · 2025Review
- Effect of COVID-19 restriction measures on multidrug resistant tuberculosis case notifications and treatment outcomes at treatment centres in Uganda.BMC infectious diseases · 2024Article
- Mycobacterium tuberculosis Rv1048c affects the biological characteristics of recombinant Mycobacterium smegmatis.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB), considered an ancient disease, is still killing one person every 21 seconds. Diagnosis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.